Tar­get­ing tox­ic pro­tein ag­gre­ga­tion, Ger­man biotech banks €12M to de­vel­op drug for rare neu­rode­gen­er­a­tive dis­or­der

The ac­cu­mu­la­tion of mis­fold­ed pro­teins is con­sid­ered the hall­mark of var­i­ous neu­rode­gen­er­a­tive dis­eases. Now, a Ger­man biotech is go­ing af­ter tox­ic pro­tein ag­gre­ga­tion in pa­tients …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER